TPMT与NUDT15变异预测炎症性疾病患者因骨髓毒性停用硫唑嘌呤
本研究为回顾性队列研究,纳入1403例新开始硫唑嘌呤治疗的成人炎症性疾病患者,依据CPIC指南判定TPMT与NUDT15代谢状态。慢/中间代谢型患者因骨髓毒性停用硫唑嘌呤的风险显著高于正常/不确定代谢型(HR=2.90,95%CI:1.58-5.31,P=0.001),校正混杂因素后关联仍显著(aHR=2.67,95%CI:1.44-4.94,P=0.002)。
要点
- 慢/中间代谢型患者因骨髓毒性停用硫唑嘌呤风险是正常/不确定代谢型的2.90倍。
- TPMT与NUDT15代谢状态可预测炎症性疾病患者硫唑嘌呤骨髓毒性停药风险。
- 该关联在校正种族、年龄、性别、适应症和初始剂量后仍显著。
核心结论
- TPMT与NUDT15代谢状态可预测炎症性疾病患者因骨髓毒性停用硫唑嘌呤的风险。
研究设计与样本
- 回顾性队列研究,纳入1403例新开始硫唑嘌呤治疗的成人炎症性疾病患者,具备遗传与临床数据。
主要发现
- 110例归类为慢/中间代谢型,1293例为正常/不确定代谢型。
- 慢/中间代谢型因骨髓毒性停用硫唑嘌呤风险更高(HR=2.90,95%CI:1.58-5.31,P=0.001)。
- 校正种族、起始年龄、性别、主要适应症和硫唑嘌呤初始日剂量后关联仍显著(aHR=2.67,95%CI:1.44-4.94,P=0.002)。
关键数值与推荐
- 采用CPIC指南判定TPMT与NUDT15代谢状态,患者分为慢/中间代谢型与正常/不确定代谢型两组。
- 基因分型使用Illumina Infinium Expanded Multi-Ethnic Genotyping Array加定制内容。
临床怎么用
- 对炎症性疾病患者启用硫唑嘌呤前可参考TPMT与NUDT15基因分型识别骨髓毒性停药高风险者。
- 慢/中间代谢型患者应加强骨髓毒性监测并遵循CPIC剂量调整建议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Azathioprine is used frequently to treat several inflammatory conditions. However, treatment is limited by adverse events-in particular, myelotoxicity. Thiopurine-S-methyltransferase (TPMT) and nudix hydrolase-15 (NUDT15) are enzymes involved in azathioprine metabolism; variants in the genes encoding these enzymes increase the risk for azathioprine myelotoxicity. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has recommended dose adjustments based on the results of TPMT and NUDT15 genotyping. However, little is known about the importance of this genetic information in routine clinical care. We hypothesized that in patients with inflammatory diseases, TPMT and NUDT15 genotype data predict the risk of discontinuing azathioprine due to myelotoxicity. This was a retrospective cohort study in 1,403 new adult azathioprine users for the management of inflammatory conditions for whom we had genetic information and clinical data. Among patients who discontinued azathioprine, we adjudicated the reason(s). Genotyping was performed using the Illumina Infinium Expanded Multi-Ethnic Genotyping Array plus custom content. We used CPIC guidelines to determine TPMT and NUDT15 metabolizer status; patients were grouped as either: (i) poor/intermediate, or (ii) normal/indeterminate metabolizers. We classified 110 patients as poor/intermediate, and 1,293 patients as normal/indeterminate metabolizers. Poor/intermediate status was associated with a higher risk for azathioprine discontinuation due to myelotoxicity compared to normal/indeterminate metabolizers (hazard ratio (HR) = 2.90, 95% confidence interval (CI): 1.58-5.31, P = 0.001). This association remained significant after adjustment for race, age at initiation, sex, primary indication, and initial daily dose of azathioprine (adjusted HR (aHR) = 2.67, 95% CI: 1.44-4.94, P = 0.002). In conclusion, TPMT and NUDT15 metabolizer status predicts discontinuation due to myelotoxicity for patients taking azathioprine for inflammatory conditions.
引用
- Dickson AL, Daniel LL, Zanussi J, et al. TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real-World Clinical Results. Clin Pharmacol Ther. 2021. PMID: 34582038. doi:10.1002/cpt.2428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。